Literature DB >> 17483252

Progressive derailment of cell cycle regulators in endometrial carcinogenesis.

N Horrée1, P J van Diest, P van der Groep, D M D S Sie-Go, A P M Heintz.   

Abstract

BACKGROUND: Derailments of the control mechanisms of the cell cycle can initiate carcinogenesis, and play a role in progression to cancer. AIM: To explore the expression of cell cycle proteins in normal, premalignant and malignant endometrial lesions representing the morphologically well defined stepwise model of human endometrial carcinogenesis
METHODS: Observational study. Paraffin-embedded specimens from inactive endometrium (n = 16), endometrial hyperplasia (n = 23) and endometrioid endometrial carcinoma (n = 39) were stained immunohistochemically for cyclin A, cyclin B1, cyclin D1, cyclin E, cdk2, p16, p21, p27, p53 and Ki67(MIB-1)). Differences in expression between the tissues, and correlation with classical prognostic factors for the carcinomas were analysed.
RESULTS: Expression of cyclin A and Ki67 gradually increased from normal through hyperplasia to carcinoma, indicating that proliferation increases over the carcinogenetic spectrum. cdk2, p16 and p21 gradually increased from normal through hyperplasia to carcinoma, indicating their potential importance in both early and late carcinogenesis. Cyclin D1, cyclin E and p53 especially increased and p27 decreased from hyperplasia to carcinoma, underlining their role in late carcinogenesis. In cancers, expression of cyclin A, p53 and Ki67 was positively correlated to grade, and cyclin A was positively correlated with cdk2, p21, Ki67, cyclin E and p53.
CONCLUSION: During (endometrioid) endometrial carcinogenesis, there is increasing proliferation paralleled by progressive derailment of cyclin B1, cyclin D1, cyclin E, p16, p21, p27, p53, and cdk2, indicating the importance of these cell cycle regulators in endometrial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483252     DOI: 10.1136/jcp.2006.043794

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

1.  Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity.

Authors:  A S McCampbell; M L Mittelstadt; R Dere; S Kim; L Zhou; B Djordjevic; P T Soliman; Q Zhang; C Wei; S D Hursting; K H Lu; R R Broaddus; C L Walker
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

2.  Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma.

Authors:  Simi Santala; Anne Talvensaari-Mattila; Ylermi Soini; Markku Santala
Journal:  Tumour Biol       Date:  2014-10-15

3.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

4.  Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.

Authors:  Osamu Nunobiki; Masatsugu Ueda; Michiko Yamamoto; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-11       Impact factor: 4.174

5.  High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma.

Authors:  Simi Santala; Anne Talvensaari-Mattila; Ylermi Soini; Maria Honkavuori-Toivola; Markku Santala
Journal:  Tumour Biol       Date:  2014-02-12

6.  The role of LEF1 in endometrial gland formation and carcinogenesis.

Authors:  Dawne N Shelton; Hubert Fornalik; Traci Neff; Soo Yeun Park; David Bender; Koen DeGeest; Xiaoming Liu; Weiliang Xie; David K Meyerholz; John F Engelhardt; Michael J Goodheart
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

7.  Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth.

Authors:  Rob D Catalano; Martin R Wilson; Sheila C Boddy; Andrew T M McKinlay; Kurt J Sales; Henry N Jabbour
Journal:  PLoS One       Date:  2011-05-12       Impact factor: 3.240

8.  Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.

Authors:  Frances Collins; Sheila MacPherson; Pamela Brown; Vincent Bombail; Alistair R W Williams; Richard A Anderson; Henry N Jabbour; Philippa T K Saunders
Journal:  BMC Cancer       Date:  2009-09-16       Impact factor: 4.430

9.  The influence of the Cyclin D1 870 G>A polymorphism as an endometrial cancer risk factor.

Authors:  Katie A Ashton; Anthony Proietto; Geoffrey Otton; Ian Symonds; Mark McEvoy; John Attia; Michael Gilbert; Ute Hamann; Rodney J Scott
Journal:  BMC Cancer       Date:  2008-09-29       Impact factor: 4.430

10.  MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC).

Authors:  Bo-Liang Liu; Kai-Xuan Sun; Zhi-Hong Zong; Shuo Chen; Yang Zhao
Journal:  Oncotarget       Date:  2016-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.